SGLT2 Inhibitors Market Report Scope & Overview:

The SGLT2 Inhibitors Market was valued at USD 18.14 Billion in 2025 and is expected to reach USD 36.80 Billion by 2035, growing at a CAGR of 7.33% from 2026–2035.

Sodium-glucose cotransporter-2 inhibitors have come a long way from their initial approval as glucose-lowering drugs in patients suffering from type 2 diabetes mellitus. A wealth of data collected over the last decade regarding clinical benefits on both a cardiac and renal level has encouraged regulatory agencies to approve the use of SGLT2 inhibitors even in the absence of diabetes, in heart failure and chronic kidney diseases. This increased scope of application allows sodium-glucose cotransporters to be considered a more desirable therapeutic option for many specialties like endocrinology, cardiology, and nephrology. An increase in the number of people with type 2 diabetes in the world, along with the updated recommendations from different medical societies for using SGLT2 inhibitors, contributes to further growth of the market.

In April 2024, Boehringer Ingelheim reported results from the Phase 3 EMPACT-MI trial showing that Jardiance (empagliflozin) reduced the risk of heart failure hospitalization by 10 percent in patients following acute myocardial infarction. This finding reinforces the expanding cardiovascular utility of SGLT2 inhibitors beyond their diabetes indication and is expected to influence prescribing patterns and future clinical guidelines for post-infarction care.

Market Size and Forecast

• Market Size in 2026E: USD 19.47 Billion

• Market Size by 2035: USD 36.80 Billion

• CAGR: 7.33% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get More Information On SGLT2 Inhibitors Market - Request Free Sample Report

SGLT2 Inhibitors Market Trends

• Clinical guidelines from major diabetes and cardiology associations increasingly position SGLT2 inhibitors as first-line therapy for patients with concomitant cardiovascular or renal risk factors.

• Regulatory approvals continue to expand beyond the original diabetes indication, with heart failure and chronic kidney disease now representing significant and growing therapeutic segments.

• Pediatric approvals for leading SGLT2 inhibitor brands are broadening the eligible patient population as type 2 diabetes prevalence rises among younger age groups.

• Online and digital pharmacy channels are expanding access to SGLT2 inhibitor therapy, particularly in regions with limited specialist infrastructure or rural healthcare access.

• Competitive pressure from other antidiabetic drug classes, including GLP-1 receptor agonists, is prompting manufacturers to differentiate SGLT2 inhibitors on cardiorenal outcomes data.

U.S. SGLT2 Inhibitors Market Outlook

The U.S. SGLT2 Inhibitors Market was valued at approximately USD 5.49 Billion in 2025 and is expected to reach approximately USD 11.06 Billion by 2035, growing at a CAGR of approximately 7.25%.

The US dominates the North America SGLT2 Inhibitors Market due to a large number of patients suffering from type 2 diabetes, well-established medical infrastructure, and prior approval of key SGLT2 inhibitor drugs such as Jardiance, Invokana, and Farxiga. Statistics released by the Centers for Disease Control and Prevention, for the period 2021 to 2023, show that 15.8% of adult US population suffers from diabetes, with about 90% of them having type 2 diabetes. This large and continuously growing patient population, coupled with good insurance coverage of specialty medicines and continuous approvals by the FDA, make the market dominate the region.

In June 2024, the U.S. Food and Drug Administration approved AstraZeneca's Farxiga (dapagliflozin) for pediatric patients aged ten years and above with type 2 diabetes, based on positive results from the Phase 3 T2GO trial. The approval addresses a rising prevalence of type 2 diabetes among children and adolescents in the United States and expands the eligible patient population for one of the market's leading branded therapies.

SGLT2 Inhibitors Market Segment Analysis

• By Drug, the Jardiance (Empagliflozin) segment dominated the SGLT2 Inhibitors Market with a 51% share of the global diabetes treatment market in 2024.

• By Indication, the Type 2 Diabetes segment dominated the SGLT2 Inhibitors Market with a 72% share in 2024, while the Cardiovascular segment is the fastest growing.

• By Distribution Channel, the Hospital Pharmacies segment dominated the SGLT2 Inhibitors Market with a 51% share in 2024, while the Online Pharmacies segment is the fastest growing with a CAGR of approximately 7.89%.

By Drug, Jardiance maintains a commanding market position

Jardiance (empagliflozin) occupied about 51% of the diabetes treatment market share globally in 2024, backed by the strong evidence from clinical studies, especially the EMPA-KIDNEY study that showed a decrease in chronic kidney disease progression or cardiovascular mortality by 28%. The approval of Jardiance for the indication of pediatric type 2 diabetes and heart failure with preserved ejection fraction has been crucial for maintaining the lead.

Expansion of the indications for Jardiance through more positive results from the ongoing clinical trials will help in maintaining its leading position during the forecast period. Other competing drugs such as Farxiga and Invokana have a considerable market presence, but neither competes with Jardiance on the basis of the strength of their clinical evidence and regulatory approvals.

By Indication, type 2 diabetes dominates, cardiovascular indications grow fastest

The type 2 diabetes segment constituted about 72% of the market share in 2024 due to the traditional use of SGLT2 inhibitors in the management of the condition. The rise in the prevalence of diabetes among adult population, which is estimated to hit 783 million by 2045, according to projections by the International Diabetes Federation, will drive demand for SGLT2 inhibitors as a result of the changing guidelines issued by the American Diabetes Association, European Association for the Study of Diabetes and European Society of Cardiology.

The cardiovascular indications segment will experience the fastest growth in the future owing to the increasing regulatory approvals for the treatment of heart failure and scientific evidence that shows reduction of major adverse cardiovascular events and heart failure hospitalizations. The May 2023 regulatory approval by FDA of the heart failure treatment by Lexicon Pharmaceuticals for its dual SGLT1/2 inhibitor sotagliflozin is one of the advancements in this indication area.

By Distribution Channel, hospital pharmacies dominate, online pharmacies grow fastest

Hospital pharmacies accounted for approximately 51% of the market in 2024, reflecting the treatment complexity associated with patients presenting multiple comorbidities. Integrated care models within hospital settings, combined with government reimbursement policies in markets including the United States and United Kingdom that guarantee coverage for hospital-administered SGLT2 inhibitor therapy, continue to support this channel's leading position.

The online pharmacies segment is projected to register the fastest growth at approximately 7.89% CAGR, driven by expanding digital health adoption, telemedicine integration, and demand for home delivery convenience. Regulatory initiatives in markets including India are extending SGLT2 inhibitor access to rural and underserved populations through digital health channels, a trend expected to accelerate as e-prescription infrastructure and virtual consultation adoption continue to expand.

Regional Analysis

North America SGLT2 Inhibitors Market Insights

The North America region is the major contributor in the global SGLT2 Inhibitors market, having garnered nearly 41% share of the market in 2025. It sets standards in terms of clinical acceptance, prices and regulatory aspects. This regional dominance is attributed to the presence of a higher prevalence of type 2 diabetes, along with healthcare infrastructure and timely approvals of major SGLT2 inhibitors such as Jardiance, Invokana and Farxiga. US accounts for more than 74% of total regional sales owing to insurance coverage and increased number of indications for FDA approval in heart failure and CKD.

Awareness regarding the cardiovascular and renal protection provided by SGLT2 inhibitors, recognized in American Diabetes Association guidelines, further drives the regional market demand.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Asia Pacific SGLT2 Inhibitors Market Insights

Asia Pacific is the fastest-growing regional market, with a projected CAGR of approximately 7.86% through the forecast period. Rapid economic development, urbanization, and associated lifestyle changes across major economies including China and India have contributed to a substantial rise in type 2 diabetes incidence. The region's aging population represents a significant structural driver, with the population of Asians aged 65 and above projected to rise from approximately 414 million in 2020 to 1.2 billion by 2060.

Governments and healthcare institutions across the Asia Pacific region are actively promoting early diagnosis, preventive care, and expanded access to advanced diabetic therapies, further supporting demand for SGLT2 inhibitor treatment. These structural demographic and policy factors are expected to sustain the region's leading growth trajectory throughout the forecast period.

Europe SGLT2 Inhibitors Market Insights

Europe represents a considerable proportion of the global SGLT2 inhibitors market, driven by the increasing incidence of type 2 diabetes, aging demographics, and increasing awareness about the cardiovascular and renal effects of SGLT2 inhibitors treatment. Western Europe, which includes countries such as Germany and France, accounts for the highest regional market share due to the well-developed healthcare framework in the region along with favorable reimbursement policies.

There will be a consistent increase in the adoption of various SGLT2 inhibitors brands in the region, such as Invokana, Jardiance, and Farxiga, not only for treating diabetes but also for heart failure and chronic kidney diseases, based on evolving clinical guidelines.

MEA & Latin America SGLT2 Inhibitors Market Insights

Latin America, the Middle East, and Africa are witnessing consistent market growth, although their market size is smaller compared to that of the other regions included in this report. Awareness about diabetes and cardiovascular diseases, increasing access to healthcare facilities, and government-sponsored initiatives are some of the factors boosting adoption in these markets. The cardiovascular care programs in Saudi Arabia contribute significantly to regional market growth, which is an indication of the government's commitment toward chronic disease management infrastructure.

In Latin America, diabetes care programs being conducted in Brazil are also boosting adoption rates due to increased access to healthcare and increased physician knowledge about SGLT2 inhibitors therapy. Although the total market size is relatively small compared to North America, Europe, and Asia Pacific, consistent government spending on chronic disease management infrastructure will ensure steady market growth.

Growth Drivers: Rising type 2 diabetes and cardiovascular disease burden accelerate demand

The key factor that drives the growth of the SGLT2 inhibitors market is an increasing prevalence of type 2 diabetes and cardiovascular disorders worldwide. In 2021 alone, there were more than 537 million people diagnosed with diabetes, and projections show that this number will rise to 783 million in 2045. The use of SGLT2 inhibitors which was initially aimed at treatment of diabetes also showed its effectiveness in management of chronic kidney disease and prevention of heart failure hospitalization risks.

SGLT2 inhibitors are supported by recommendations for 2025 from the American Diabetes Association in treatment of type 2 diabetes with comorbidity of cardiovascular disease, therefore, becoming an integral part of treatment regimen. As a result of demographic changes and sedentary lifestyles and diets, the prevalence of chronic diseases increases and SGLT2 inhibitors are becoming a more common choice of treatment for healthcare systems.

Restraints: Safety concerns and established competition constrain broader adoption

The market for SGLT2 inhibitors is subject to stiff competition, coming from existing diabetes treatments such as metformin, sulfonylurea, DPP-4 inhibitors, and GLP-1 receptor agonist therapies. Health care providers and payers prefer these other drug options because of their lower costs and the longer history of safety when used in patients. Also, there have been apprehensions about SGLT2 inhibitor side effects, which include UTIs, dehydration, and rare cases of complications like lower limb amputation.

The need for robust local clinical evidence in some countries represents another barrier to market access for new entrants, especially those that seek to enter regions with high standards for scientific evidence. The combination of these barriers – cost sensitivity, safety concerns, and complex regulations – continues to limit the rate of adoption of SGLT2 inhibitors.

Opportunities: Expanding indications and digital health integration present meaningful growth avenues

Growth of indications from diabetes to heart failure and chronic kidney disease is another significant opportunity for SGLT2 inhibitors suppliers. The combination of clinical data gathered from trials such as EMPA-KIDNEY and updates in recommendations by European Society of Cardiology adds weight to the clinical value of using SGLT2 inhibitors in a wider segment of patients compared to initial indication for the drug category.

Increasing digitization of healthcare services is yet another opportunity available for SGLT2 inhibitor suppliers in markets looking to provide specialist-level care to their rural and less developed segments through the use of telemedicine and digital health platforms. As more countries embrace online pharmacy solutions and build up the infrastructure for online prescription services, manufacturers that have the ability to work with this channel will be able to gain from demand growth.

Recent Developments:

• 2023: In May 2023, the FDA approved Lexicon Pharmaceuticals' sotagliflozin, the first dual SGLT1/2 inhibitor, for heart failure, underscoring the expanding role of SGLT2 inhibitors in cardiovascular disease treatment.

• 2023: In September 2023, Eli Lilly and Boehringer Ingelheim announced FDA approval for Jardiance based on its efficacy in reducing the risk of cardiovascular death and hospitalization resulting from chronic kidney disease.

• 2024: In April 2024, Boehringer Ingelheim reported Phase 3 EMPACT-MI trial results showing that Jardiance reduced the risk of heart failure hospitalization by 10% in patients following acute myocardial infarction.

• 2024: In June 2024, the FDA approved AstraZeneca's Farxiga (dapagliflozin) for pediatric patients aged ten years and above with type 2 diabetes, based on results from the Phase 3 T2GO trial.

SGLT2 Inhibitors Market Key Players

• Boehringer Ingelheim International GmbH

• Sanofi

• AstraZeneca

• TheracosBio, LLC

• Merck & Co., Inc.

• Glenmark Pharmaceuticals Ltd.

• Lexicon Pharmaceuticals, Inc.

• Eli Lilly and Company

• Johnson & Johnson Services, Inc.

• Bristol-Myers Squibb Company

• Novo Nordisk A/S

• Pfizer Inc.

• Novartis AG

• Takeda Pharmaceutical Company Limited

• GlaxoSmithKline plc

• Teva Pharmaceutical Industries Ltd.

• Zydus Lifesciences Ltd.

• Dr. Reddy's Laboratories

• Sun Pharmaceutical Industries Ltd.

• Cipla Limited

SGLT2 Inhibitors Market Report Scope: